Volume 17, Issue 2 (June-2025 2025)                   Iranian Journal of Blood and Cancer 2025, 17(2): 99-109 | Back to browse issues page

XML Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Kumar Singh V, awasthi S, Haria J, Singh P. Efficacy and Safety of Ensartinibin ALK-positive Non-Small Cell Lung Cancer Patients: A Systematic Review and Meta-analysis. Iranian Journal of Blood and Cancer 2025; 17 (2) :99-109
URL: http://ijbc.ir/article-1-1715-en.html
Efficacy and Safety of Ensartinibin ALK-positive Non-Small Cell Lung Cancer Patients: A Systematic Review and Meta-analysis
Vinod Kumar Singh1 , Seema Awasthi1 , Jigar Haria *2 , Prithpal Singh1
1- TMMC&RC, Teerthanker Mahaveer University, Moradabad, UP, India.
2- TMMC&RC, Teerthanker Mahaveer University, Moradabad, UP, India. , jigarharia332@gmail.com
Abstract:   (862 Views)

Background: NSCLC accounts for a significant proportion of global cancer mortality, with ALK-positive NSCLC constituting approximately 9% of cases. Ensartinib has demonstrated promising systemic and central CNS efficacy in clinical trials.
Methods: A systematic review and meta-analysis were performed following PRISMA guidelines, using PubMed, Web of Science, Cochrane, and Scopus databases. RCTs and cohort studies reporting outcomes such as OS, PFS, RR, and adverse events in ALK-positive NSCLC patients treated with ensartinib were included. Data were synthesized using CMA software, and heterogeneity was assessed using chi-square tests and I² statistics.
Results: Six studies encompassing 1,246 patients met the inclusion criteria. Pooled analysis revealed a RR of 56% (95% CI: 45–67%) and significant improvements in OS (Mean = 41.71 months, 95% CI: 31.64–51.77) and PFS (Mean = 8.88 months, 95% CI: 4.48–13.28). Common adverse events included rash (69%), nausea (19%), vomiting (15%), and transaminitis, with ALT (49%) and AST (42%) elevations.
Conclusions: Ensartinib exhibits significant efficacy in improving OS and PFS in ALK-positive NSCLC, with manageable adverse effects. Its robust systemic and CNS activity supports its clinical utility as a second-generation ALK inhibitor. Further studies with bigger, diverse populations are warranted to validate these findings and explore long-term outcomes.

./files/site1/files/Suplemenatry_Table_1.pdf
 

Keywords: NSCLC, Immunotherapy, Biomarkers, EGFR, Metastasis
Full-Text [PDF 667 kb]   (1063 Downloads)    
: Review Article | Subject: Adults Hematology & Oncology
Received: 2025/05/6 | Accepted: 2025/06/14 | Published: 2025/06/30
References
1.    Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424. doi:10.3322/caac.21492 [DOI:10.3322/caac.21492]
2.    Gridelli C, Peters S, Sgambato A, Casaluce F, Adjei AA, Ciardiello F. ALK inhibitors in the treatment of advanced NSCLC. Cancer Treat Rev. 2014;40(2):300-306. doi:10.1016/j.ctrv.2013.07.002 [DOI:10.1016/j.ctrv.2013.07.002]
3.    Lee JK, Park HS, Kim D-W, et al. Comparative analyses of overall survival in patients with anaplastic lymphoma kinase-positive and matched wild-type advanced nonsmall cell lung cancer. Cancer. 2012;118(14):3579-3586. doi:10.1002/cncr.26668 [DOI:10.1002/cncr.26668]
4.    Yoshida T, Oya Y, Tanaka K, et al. Clinical impact of crizotinib on central nervous system progression in ALK-positive non-small lung cancer. Lung Cancer. 2016;97:43-47. doi:10.1016/j.lungcan.2016.04.006 [DOI:10.1016/j.lungcan.2016.04.006]
5.    Shaw AT, Kim D-W, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med. 2013;368(25):2385-2394. doi:10.1056/NEJMoa1214886 [DOI:10.1056/NEJMoa1214886]
6.    Lin JJ, Riely GJ, Shaw AT. Targeting ALK: precision medicine takes on drug resistance. Cancer Discov. 2017;7(2):137-155. doi:10.1158/2159-8290.CD-16-1123 [DOI:10.1158/2159-8290.CD-16-1123]
7.    Costa DB, Kobayashi S, Pandya SS, et al. CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib. J Clin Oncol. 2011;29(15):e443-5. doi:10.1200/JCO.2010.34.1313 [DOI:10.1200/JCO.2010.34.1313]
8.    Castellanos EH, Horn L. Re-Evaluating Progression in an Era of Progress: A Review of First- and Second-Line Treatment Options in Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer. Oncologist. 2016;21(6):755-761. doi:10.1634/theoncologist.2015-0396 [DOI:10.1634/theoncologist.2015-0396]
9.    Shaw AT, Kim D-W, Mehra R, et al. Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med. 2014;370(13):1189-1197. doi:10.1056/NEJMoa1311107 [DOI:10.1056/NEJMoa1311107]
10.   Kim D-W, Tiseo M, Ahn M-J, et al. Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial. J Clin Oncol. 2017;35(22):2490-2498. doi:10.1200/JCO.2016.71.5904 [DOI:10.1200/JCO.2016.71.5904]
11.   Ou S-HI, Ahn JS, De Petris L, et al. Alectinib in Crizotinib-Refractory ALK-Rearranged Non-Small-Cell Lung Cancer: A Phase II Global Study. J Clin Oncol. 2016;34(7):661-668. doi:10.1200/jco.2015.63.9443 [DOI:10.1200/JCO.2015.63.9443]
12.   Horn L, Infante JR, Reckamp KL, et al. Ensartinib (X-396) in ALK-Positive Non-Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study. Clin Cancer Res. 2018;24(12):2771-2779. doi:10.1158/1078-0432.CCR-17-2398 [DOI:10.1158/1078-0432.CCR-17-2398]
13.   Page M, McKenzie J, Bossuyt P, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. doi:10.1136/bmj.n71 [DOI:10.1136/bmj.n71]
14.   Study Quality Assessment Tools | NHLBI, NIH. Accessed August 7, 2022. https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools
15.   Horn L, Wang Z, Wu G, et al. Ensartinib vs Crizotinib for Patients With Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Randomized Clinical Trial. JAMA Oncol. 2021;7(11):1617-1625. doi:10.1001/jamaoncol.2021.3523 [DOI:10.1001/jamaoncol.2021.3523]
16.   Yang Y, Zhou J, Zhou J, et al. Efficacy, safety, and biomarker analysis of ensartinib in crizotinib-resistant, ALK-positive non-small-cell lung cancer: a multicentre, phase 2 trial. Lancet Respir Med. 2020;8(1):45-53. doi:10.1016/S2213-2600(19)30252-8 [DOI:10.1016/S2213-2600(19)30252-8]
17.   Ai X, Wang Q, Cheng Y, et al. Safety but Limited Efficacy of Ensartinib in ROS1-Positive NSCLC: A Single-Arm, Multicenter Phase 2 Study. J Thorac Oncol. 2021;16(11):1959-1963. doi:10.1016/j.jtho.2021.06.023 [DOI:10.1016/j.jtho.2021.06.023]
18.   Yuan X, Wang Y, Yang M, et al. A retrospective study of ensartinib-treated ALK-positive locally advanced or metastatic NSCLC patients in China. Lung Cancer Manag. 2023;12(4):LMT61. doi:10.2217/lmt-2023-0005 [DOI:10.2217/lmt-2023-0005]
19.   Ma Y, Pan H, Liu Y, et al. Ensartinib in advanced ALK-positive non-small cell lung cancer: a multicenter, open-label, two-staged, phase 1 trial. J Thorac Dis. 2022;14(12):4751-4762. doi:10.21037/jtd-22-1606 [DOI:10.21037/jtd-22-1606]
20.   Zheng J, Wang T, Yang Y, et al. Updated overall survival and circulating tumor DNA analysis of ensartinib for crizotinib-refractory ALK-positive NSCLC from a phase II study. Cancer Commun (Lond). 2024;44(4):455-468. doi:10.1002/cac2.12524 [DOI:10.1002/cac2.12524]
Add your comments about this article : Your username or Email:
CAPTCHA
Send email to the article author

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2026 All Rights Reserved | Iranian Journal of Blood and Cancer

Designed & Developed by : Yektaweb